Related Experiment Video
Updated: Apr 25, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[Increased thromboembolic risk in atrial fibrillation and stroke prevention in women]
Insights
Women with atrial fibrillation (AF) face higher stroke risks, especially when using vitamin K antagonists. Newer anticoagulants offer similar efficacy and bleeding risk for both sexes, improving stroke prevention in women.
Area of Science:
- Cardiology
- Neurology
- Epidemiology
Context:
- Female sex is a known risk factor for atrial fibrillation (AF) and its associated ischemic stroke.
- Women with AF often have higher rates of comorbidities like diabetes and heart failure.
- While anticoagulation rates are similar between sexes, women over 75 using vitamin K antagonists (VKAs) experience less stable anticoagulation and higher stroke risk.
Purpose:
- To review epidemiological and pathophysiological data on thromboembolic event risks in women with AF.
- To discuss therapeutic challenges in stroke prevention for women with AF.
- To compare the efficacy and safety of new oral anticoagulants versus VKAs in women.
Summary:
- Women with AF have a higher risk of ischemic stroke, partly due to comorbidities.
- Women using VKAs have less stable anticoagulation and increased stroke risk, particularly those aged 75+.
- New oral anticoagulants demonstrate comparable efficacy and bleeding risk to warfarin in both sexes for nonvalvular AF stroke prevention.
Impact:
- Highlights the specific risks of AF-related stroke in women.
- Informs clinical practice regarding anticoagulation choices for women with AF.
- Emphasizes the benefits of newer anticoagulants for stroke risk reduction in female AF patients.
Abstract:
Female sex is a recognized risk factor for atrial fibrillation (AF) and ischemic stroke associated with AF, which is in part related to higher prevalence of comorbidities such as diabetes and heart failure. In recent years the proportion of anticoagulated women with AF is similar to that for men. Women receiving vitamin K antagonists (VKA) are more prone to have unstable anticoagulation and experience stroke during such prevention, in particular in individuals aged > or = 75 years. New oral anticoagulants recently approved for prevention of stroke in patients with nonvalvular AF are at least as efficacious as dose-adjusted warfarin in both women and men. The risk of bleeding on these new drugs is also similar in both sexes. The current review summarizes the epidemiological and pathophysiological data on the risk of thromboembolic events in women with AF and therapeutic challenges of stroke prevention in women.
More Related Videos
28:13Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
08:10Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management
Venous Thrombosis I: Introduction
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...